Drug Trial Radar · NCT03004469
Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia
Last checked: Nov 19, 2026Latest source record: Jun 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
458
Actual
Start
Aug 2, 2016
Primary completion
Mar 5, 2018
Study completion Mar 5, 2018
Sponsor
- Lead sponsor
- Polichem S.A.Industry
- Sponsor type
- Industry
- First posted
- Dec 28, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to confirm the clinical efficacy and the safety of P-3074 in participants with androgenetic alopecia.
Conditions
- Alopecia, Androgenetic
Interventions
P-3074Drug
FinasterideDrug
P-3074 VehicleDrug
Finasteride PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adjusted Mean Change From Baseline in Hair Growth Assessed by Target Area Hair Count (TAHC) in the Vertex at Week 24Time frame: Baseline and Week 24
Locations
46 sites in 5 countries. Site status is shown where the registry gives one.
Site #102
Brussels, Belgium
Site #103
Brussels, Belgium
Site #104
Brussels, Belgium
Site #101
Ghent, Belgium
Site #211
Augsburg, Germany
Site #202
Berlin, Germany
Site #212
Berlin, Germany
Site #216
Bochum, Germany
Site #210
Dresden, Germany
Site #217
Dresden, Germany
Site #221
Dresden, Germany
Site #203
Düsseldorf, Germany
Site #204
Freiburg im Breisgau, Germany
Site #206
Hamburg, Germany
Site #214
Hamburg, Germany
Site #218
Hamburg, Germany
Site #213
Hanover, Germany
Site #215
Karlsruhe, Germany
Site #220
Lübeck, Germany
Site #208
Münster, Germany
Site #219
Potsdam, Germany
Site #209
Schwerin, Germany
Site #201
Wuppertal, Germany
Site #303
Budapest, Hungary
Site #309
Budapest, Hungary
Site #302
Debrecen, Hungary
Site #308
Sátoraljaújhely, Hungary
Site #301
Szolnok, Hungary
Site #307
Szombathely, Hungary
Site #401
Chelyabinsk, Russia
Site #402
Moscow, Russia
Site #407
Moscow, Russia
Site #411
Moscow, Russia
Site #409
Rostov-on-Don, Russia
Site #403
Ryazan, Russia
Site #406
Saint Petersburg, Russia
Site #408
Saint Petersburg, Russia
Site #410
Yaroslavl, Russia
Site #503
Alicante, Spain
Site #505
Barakaldo, Spain
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.